More about Constructive Bio
Constructive Bio is a synthetic biology and biotechnology startup founded in 2022, emerging from the MRC Laboratory of Molecular Biology in Cambridge, UK. The company focuses on whole genome writing and genetic code reprogramming to develop programmable biomolecules that exceed natural capabilities. Headquartered in Whittlesford, Cambridge, Constructive Bio utilizes a dual-technology platform that includes de-novo genome synthesis and engineered protein translation. The company's patented Syn61 strain features a fully synthetic *E. coli* genome, allowing for the precise production of novel proteins, enzymes, and biopolymers. Constructive Bio's technologies support various applications, including next-generation therapeutics, sustainable industrial biomanufacturing, and innovations in agritech. The team, led by CEO Ola Wlodek, is expanding and has secured significant funding to support its growth and research initiatives.
Live roles
Alert me when Constructive Bio posts a new role Email me when this changes
Similar Cambridge companies
Full directory →- Kymab / Sanofi Cambridge 47 live
- AstraZeneca 13 live
Cambridge-headquartered global pharma; major presence at the Cambridge Biomedical Campus. Heavy AI/ML hiring across genetics, drug discovery and biologics engineering.
- GSK 6 live
Global pharma; Stevenage R&D campus is the company's largest UK research site. Active in AI/ML for drug discovery, translational data, and oncology pharmacology.
- Illumina 6 live
Cambridge-based (Chesterford Research Park) arm of Illumina developing DNA sequencing instruments and technology.
- Tailor Bio 4 live
- Healx 2 live
Cambridge AI-for-rare-disease scale-up; ML platform for drug repurposing and combination discovery. Strong ML/data hiring track record.